Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eberswalde – page 38

1 792 clinical trials in Eberswalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eberswalde at a glance
1 792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 792 trials in Eberswalde

Open in trial search

Study of Sarilumab for Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sarilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts
  • Sponsor:Cutiss AG

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Study of Opevesostat, Olaparib, and Cabazitaxel in Patients with Advanced Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Study of tovorafenib (DAY101) in children and young adults aged 6 months to 25 years with brain tumors and other solid tumors that have RAF gene changes

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Tovorafenib
  • Sponsor:Day One Biopharmaceuticals Inc.

Study on Preventing Blood Clots in Patients with New-Onset Post-Operative Atrial Fibrillation after CABG Using Apixaban and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Icahn School Of Medicine At Mount Sinai

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Poractant Alfa
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study on the Effect of Durvalumab and Tremelimumab with Radioactive Glass Spheres in Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Klinikum Der Universitat Munchen AöR

Ovarian cancer+2

Recruiting

Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TUB-040
  • Sponsor:Gilead Sciences Inc.

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Epizyme Inc.

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Crisantaspase
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Eberswalde

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on Diffuse Large B-Cell Lymphoma (DLBCL) and its various subtypes, evaluating innovative combination therapies for elderly patients.

  • Treatment optimization for older adults
  • B-cell lymphoma variants
  • Targeted therapy combinations

The study explores the effectiveness of combining acalabrutinib with standard lymphoma treatments to improve outcomes in patients over 60 and 80 years of age.

02 Specialized Lymphoma Research

Investigation of multiple B-cell lymphoma subtypes, including rare variants such as primary cutaneous, intravascular, and mediastinal forms.

  • Novel therapeutic approaches
  • Rare lymphoma variants
  • Treatment response assessment

Research aims to enhance progression-free survival through targeted therapeutic strategies.

03 Personalized Medicine

Advancing treatment protocols for elderly lymphoma patients with focus on reduced-intensity therapy combinations.

  • Age-adapted treatments
  • Quality of life considerations
  • Therapeutic efficacy

Studies evaluate modified treatment regimens designed specifically for older adults who cannot tolerate standard intensive therapies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.